Injectable manufacturing specialist Symbiosis Pharmaceutical Services has successfully completed a scheduled inspection from the UK Government Regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).

The contract manufacturing organization (CMO) received no critical or major observations.

Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products (IMPs) for clinical trials. In a further boost to support the growth and strategic development of the company, it received confirmation of continued authorization for the GMP-manufacture of aseptically filled licensed commercial products following initial approval of the commercial manufacturer/importer (MIA) license last year.

The regulatory inspection and approval of Symbiosis’ Scotland-based facility comes in the wake of several high profile pull outs and inspection failures at sterile pharmaceutical manufacturing facilities globally.